Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
AOD-9604 vs Survodutide
An educational, source-based comparison of AOD-9604 and Survodutide — how each peptide works, what it's researched for, and what to know before going deeper.
A modified 16-amino-acid fragment (177–191) of human growth hormone, engineered to retain the lipolytic activity of GH without its growth or insulin-resistance effects. Research suggests it stimulates lipolysis and inhibits lipogenesis.
- Obesity (clinical trials did not meet endpoints)
- Osteoarthritis / cartilage repair (current research direction)
- Localized adipose research
- • Not FDA-approved as a therapeutic.
- • Has GRAS status in some food contexts (Australia), not equivalent to drug approval.
A dual agonist of the GLP-1 and glucagon receptors. The glucagon arm adds an energy-expenditure component on top of GLP-1's appetite and glycemic effects.
- Chronic weight management
- MASH / fatty liver disease
- Type 2 diabetes
- • Investigational; not yet FDA-approved.
- • GI side effects are dose-limiting.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| AOD-9604 | AOD9604 in obesity: phase 2b results | Obesity | 2010 | Did not achieve significant weight loss vs. placebo in primary endpoint. |
| Survodutide | Survodutide for obesity (Phase 2) | The Lancet Diabetes & Endocrinology | 2024 | Up to ~19% mean weight loss at 46 weeks. |
Side-effect & safety grid
- Not FDA-approved as a therapeutic.
- Has GRAS status in some food contexts (Australia), not equivalent to drug approval.
- Investigational; not yet FDA-approved.
- GI side effects are dose-limiting.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
AOD-9604 vs Survodutide — Key differences
- Class: AOD-9604 is classified as Metabolic · Lipolysis, while Survodutide is Metabolic · Incretin.
- Primary research focus: AOD-9604 — obesity (clinical trials did not meet endpoints); Survodutide — chronic weight management.
- Tag: Fat loss vs Weight loss.